- Home
- LMFA vs MYNZ Comparison
LMFA vs MYNZ Comparison
Compare LMFA & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMFA
- MYNZ
- Stock Information
- Founded
- LMFA 2008
- MYNZ 2021
- Country
- LMFA United States
- MYNZ Germany
- Employees
- LMFA N/A
- MYNZ N/A
- Industry
- LMFA Finance: Consumer Services
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- LMFA Finance
- MYNZ Health Care
- Exchange
- LMFA Nasdaq
- MYNZ Nasdaq
- Market Cap
- LMFA 7.0M
- MYNZ 7.2M
- IPO Year
- LMFA 2015
- MYNZ 2021
- Fundamental
- Price
- LMFA $1.43
- MYNZ $3.20
- Analyst Decision
- LMFA Hold
- MYNZ Buy
- Analyst Count
- LMFA 1
- MYNZ 2
- Target Price
- LMFA N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- LMFA 36.4K
- MYNZ 105.1K
- Earning Date
- LMFA 05-15-2025
- MYNZ 05-06-2025
- Dividend Yield
- LMFA N/A
- MYNZ N/A
- EPS Growth
- LMFA N/A
- MYNZ N/A
- EPS
- LMFA N/A
- MYNZ N/A
- Revenue
- LMFA $10,555,948.00
- MYNZ $893,991.00
- Revenue This Year
- LMFA $0.98
- MYNZ $42.95
- Revenue Next Year
- LMFA $4.31
- MYNZ N/A
- P/E Ratio
- LMFA N/A
- MYNZ N/A
- Revenue Growth
- LMFA N/A
- MYNZ N/A
- 52 Week Low
- LMFA $1.02
- MYNZ $0.18
- 52 Week High
- LMFA $6.11
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- LMFA 57.42
- MYNZ 40.90
- Support Level
- LMFA $1.11
- MYNZ $3.03
- Resistance Level
- LMFA $1.50
- MYNZ $3.31
- Average True Range (ATR)
- LMFA 0.13
- MYNZ 0.35
- MACD
- LMFA 0.04
- MYNZ 0.06
- Stochastic Oscillator
- LMFA 85.36
- MYNZ 61.80
About LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.